Rapamycin Combined with Anti-CD45RB mAb and IL-10 or with G-CSF Induces Tolerance in a Stringent Mouse Model of Islet Transplantation by Gagliani, Nicola et al.
Rapamycin Combined with Anti-CD45RB mAb and IL-10
or with G-CSF Induces Tolerance in a Stringent Mouse
Model of Islet Transplantation
Nicola Gagliani
1,2,3, Silvia Gregori
2, Tatiana Jofra
1, Andrea Valle
1,3, Angela Stabilini
1, David M.
Rothstein
4, Mark Atkinson
5, Maria Grazia Roncarolo
2,3, Manuela Battaglia
1*
1San Raffaele Diabetes Research Institute, San Raffaele Scientific Institute, Milan, Italy, 2San Raffaele Telethon Institute for Gene Therapy, San Raffaele Scientific Institute,
Milan, Italy, 3Vita-Salute San Raffaele University, Milan, Italy, 4Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United
States of America, 5Department of Pathology, The University of Florida, Gainesville, Florida, United States of America
Abstract
Background: A large pool of preexisting alloreactive effector T cells can cause allogeneic graft rejection following
transplantation. However, it is possible to induce transplant tolerance by altering the balance between effector and
regulatory T (Treg) cells. Among the various Treg-cell types, Foxp3
+Treg and IL-10–producing T regulatory type 1 (Tr1) cells
have frequently been associated with tolerance following transplantation in both mice and humans. Previously, we
demonstrated that rapamycin+IL-10 promotes Tr1-cell–associated tolerance in Balb/c mice transplanted with C57BL/6
pancreatic islets. However, this same treatment was unsuccessful in C57BL/6 mice transplanted with Balb/c islets (classified
as a stringent transplant model). We accordingly designed a protocol that would be effective in the latter transplant model
by simultaneously depleting effector T cells and fostering production of Treg cells. We additionally developed and tested a
clinically translatable protocol that used no depleting agent.
Methodology/Principal Findings: Diabetic C57BL/6 mice were transplanted with Balb/c pancreatic islets. Recipient mice
transiently treated with anti-CD45RB mAb+rapamycin+IL-10 developed antigen-specific tolerance. During treatment,
Foxp3
+Treg cells were momentarily enriched in the blood, followed by accumulation in the graft and draining lymph node,
whereas CD4
+IL-10
+IL-4
2 T (i.e., Tr1) cells localized in the spleen. In long-term tolerant mice, only CD4
+IL-10
+IL-4
2 T cells
remained enriched in the spleen and IL-10 was key in the maintenance of tolerance. Alternatively, recipient mice were
treated with two compounds routinely used in the clinic (namely, rapamycin and G-CSF); this drug combination promoted
tolerance associated with CD4
+IL-10
+IL-4
2 T cells.
Conclusions/Significance: The anti-CD45RB mAb+rapamycin+IL-10 combined protocol promotes a state of tolerance that is
IL-10 dependent. Moreover, the combination of rapamycin+G-CSF induces tolerance and such treatment could be readily
translatable into the clinic.
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Introduction
T regulatory (Treg) cells typically control immune responses,
and they are also capable of establishing tolerance to non-self
molecules that are deliberatively introduced into the host, as
occurs in allogeneic transplantation settings [1,2]. However,
endogenous Treg cells do not usually occur in sufficient numbers
to control the large population of pre-existing alloreactive T
effector cells in recipients, and this imbalance increases the
potential for graft rejection [3]. Immunosuppressive drugs block/
deplete alloreactive T effector cells, and are currently used in the
clinic to prevent graft rejection [4]. However, most of these drugs
necessitate life-long administration and thus increase the risk of
undesirable side effects (e.g., infections and lymphomas). In
addition, some immunosuppressive drugs, such as cyclosporine A
and FK506, are known to interfere not only with the function of
allogeneic T cells but also with that of Treg cells [5]. The twin
priorities of overcoming interference with Treg cells and of
inducing long-term transplant tolerance argue strongly for a
therapeutic approach that simultaneously enables the depletion of
pre-existing alloantigen specific T cells and the fostering of Treg
cells [1,6].
The CD4
+ Treg cells that have most often been associated with
tolerance to allogeneic transplantation in mice and humans are
CD4
+CD25
+Foxp3
+ (Foxp3
+) Treg cells and T regulatory type 1
(Tr1) cells. The expression of CD25 is considered essential for the
complete fitness of Foxp3
+ Treg cells [7]. In contrast, Tr1 cells do
not constitutively express CD25 and Foxp3, and are defined by the
production of high levels of IL-10 and the absence of IL-4, as well
as by the predominant occurrence of control immune responses
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+-Treg
and Tr1 cells are considered to be two distinct types of Treg cells
[10,11].
We previously established two distinct models of islet trans-
plantation on the basis of the mean rejection time of untreated
transplanted mice, whereby one model could be considered as
more stringent than the other [12]. Thus differentiated, these two
models were used to test different compounds, either alone or in
combination, in order to define the optimal protocol for inducing
stable long-term tolerance. Moreover, we attempted to design a
clinically relevant protocol by restricting our testing to compounds
that were already in use within current clinical settings.
Rapamycin is a non-calcineurin-based inhibitor that is currently
used in a variety of immunosuppressive strategies, in combination
with other compounds, to block solid organ graft rejection [13]. Of
note, this drug not only blocks T cell activation, but also selectively
allows for proliferation as well as fostering the suppressive function
of Foxp3
+ Treg cells [14,15]. IL-10 is a cytokine with potent anti-
inflammatory properties that can induce Tr1 cells in vitro [12,16].
We previously showed that rapamycin+IL-10 treatment leads to
long-term tolerance associated with the induction of Tr1 cells in
the non-stringent model of islet transplant [17]. Therefore, a
primary goal of this current effort is to test rapamycin+IL-10
therapy in the more stringent mouse model of islet transplantation.
Considering the high frequency of alloreactive T cells in the
recipient mice of this model, we hypothesized that a depleting
agent could improve the efficacy of rapamycin+IL-10 treatment.
Therefore, from the several depleting agents available today, we
chose to test anti-CD45RB mAb, which transiently depletes
alloreactive T cells from the blood [18,19] and, more importantly,
has the capacity to increase the Treg-cell suppressive function
[20].
Another promising tolerogenic molecule is the granulocyte-
colony stimulating factor (G-CSF), which is currently used in
clinical practice for the mobilization of bone marrow hematopoi-
etic stem cells. In vivo administration of G-CSF blocks graft versus
host disease (GvHD) [21], and prevents type 1 diabetes
development [22,23]. The effect of this molecule in a setting of
islet transplantation has never been investigated, and the issue of
whether its tolerogenic effect is associated with increases in IL-10
release or with Foxp3
+ Treg-cell expansion is controversial
[21,22].
The current study demonstrates that, in a stringent model of
islet transplantation, the combination of anti-CD45RB mAb with
rapamycin+IL-10 promotes a unique state of tolerance IL-10
dependent and associated with two types of Treg cells. Moreover,
the combination of rapamycin+G-CSF induces Tr1 cell-associated
tolerance. Considering that both rapamycin and G-CSF are
currently in clinical use, we believe these data have powerful
clinical implications.
Results
The combined protocol (anti-CD45RB
mAb+rapamycin+IL-10) promotes tolerance in a
stringent mouse model of islet transplant
Rapamycin+IL-10 treatment promotes transplantation toler-
ance in chemically-induced diabetic BALB/c (BALB) mice
transplanted with C57BL/6 (B6) islets (B6RBALB) [17]. In a
more stringent model of islet transplantation (BALBRB6)
rapamycin+IL-10, administered in accordance with a previously
used schedule and dose regimen [17], did not promote tolerance
(Figure 1A). We hypothesized that a therapy capable of combining
deletion with immunomodulant effects would promote long-term
tolerance in this more stringent model [1,6]. Anti-CD45RB mAb
transiently depletes circulating T cells [18], which are responsible
for allograft rejection [19,24]; at the same time, it fits the
regulatory action of Treg cells [20,25]. Accordingly, three peri-
transplant injections of anti-CD45RB mAb duly promoted long-
term acceptance of the graft in 75% of BALB mice transplanted
with B6 islets (B6RBALB model) (Figure 1B). This treatment
transiently reduced the number of circulating lymphocytes and
significantly increased the expression of CTLA-4 on Treg cells in
the spleen and in graft-draining lymph nodes (dLN) (data not
shown), as previously demonstrated [20].
We then tested the efficacy of anti-CD45RB mAb treatment in
the stringent mouse transplantation model (BALBRB6). Although
the mAb was highly efficient in blocking early graft rejection (i.e.,
at 15–30 days following islet transplant), it subsequently lost
efficacy (i.e., at 60 days or more following islet transplant)
(Figure 1C). On the basis of these data, we designed a combined
protocol; to a peri-transplant treatment comprising of anti-
CD45RB mAb, we added a 30-day therapy with rapamycin+IL-
10. When tested separately, neither rapamycin+IL-10 nor anti-
CD45RB mAb attained long-term graft survival in the stringent
model of islet transplant (Figure 1A and 1C). Nonetheless, the
combined protocol (anti-CD45RB mAb+rapamycin+IL-10) pro-
longed graft survival in 73% of the mice to 100 days following
transplantation (Figure 1D). Significantly, upon injection of donor-
derived splenocytes (i.e., a donor-derived antigen boost) 100 days
after transplant, only 4 out of 21 mice with a long-term functioning
graft rejected the allogeneic islets. Overall, the proportion of mice
treated with the combined protocol that achieved long-term
tolerance (i.e., acceptance of the graft and maintenance of graft
survival upon donor-derived Ag re-challenge in the absence of any
active immunosuppressive treatment), was 58% (Figure 1D). We
accordingly conclude that the combination of rapamycin+IL-10
treatment with anti-CD45RB mAb promotes long-term tolerance
in a stringent mouse model of islet transplant.
Engraftment of allogeneic islets endorsed by the
combined protocol is associated with CD4
+CD25
+Foxp3
+
and CD4
+IL-10
+IL-4
2 cells, which localize in different
tissues
Our next step was to investigate the immunological outcome of
the joint administration of anti-CD45RB mAb and rapamycin+IL-
10. Kinetic analysis of the peripheral blood of transplanted and
treated mice revealed that the number (data not shown) and the
frequency of circulating CD4
+ and CD8
+ T cells was reduced
(Figure 2A) as a result of specific CD45RB
high T-cell targeting by
the anti-CD45RB mAb (Figure 2B), both in mice treated with the
combined protocol and in those treated with anti-CD45RB mAb
alone. In addition, the selective depletion of CD45RB
high cells led
to an enrichment of circulating CD4
+CD25
+Foxp3
+ Treg cells
(Figure 2B). All these immunological phenomena were transient,
since CD4
+, CD8
+, and CD4
+CD25
+Foxp3
+ Treg cells returned
to their physiological basal levels 30 days from the beginning of the
treatment (Figure 2).
Given the known activity of rapamycin on Foxp3
+ Treg cells,
and of IL-10 on Tr1 cells [26], we analyzed these two Treg-cell
types in the spleen, in the lymph-node that drain the graft (dLN),
and in the graft of treated mice at the end of the treatment (i.e., 30
days following transplantation). These analyses showed that the
frequency of Foxp3
+ Treg cells increased both in dLN and in the
graft, but not in the spleen of mice treated with the combined
protocol (Figure 3). In contrast, CD4
+IL-10
+IL4
2 (i.e., Tr1 cells)
cells were enriched in the spleen, but not in the dLN nor in the
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PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e28434Figure 1. Anti-CD45RB mAb+rapamycin+IL-10 induce long-term tolerance in a stringent model of islet transplantation. (A) Diabetic
C57BL/6 (B6) mice were transplanted with BALB/c (BALB) islets (BALBRB6). The transplanted mice were either left untreated (n=49) or treated with
rapamycin+IL-10 (n=30). The treatment was withdrawn 30 days from transplantation. Overall graft survival is shown. (B) Diabetic BALB mice were
transplanted with B6 islets (B6RBALB). The transplanted mice were either left untreated (n=17) or treated with anti-CD45RB mAb (n=17) at days 0, 3
and 5 from transplantation. Overall graft survival is shown. (C) Diabetic B6 mice were transplanted with BALB islets (BALBRB6). The transplanted mice
were either left untreated (n=49) or treated with the anti-CD45RB mAb (n=8) at days 0, 3 and 5 from transplantation. Overall graft survival is shown.
(D) Diabetic B6 mice were transplanted with BALB islets (BALBRB6). The transplanted mice were either left untreated (n=49) or treated with anti-
CD45RB mAb (at days 0, 3 and 5 from transplantation)+rapamycin+IL-10 (n=29) for 30 days. One hundred days from transplantation, 30610
6
splenocytes isolated from BALB mice were injected in tolerant mice to boost their immune system. Mice that were normoglycemic 40–50 days after
the boost were considered tolerant. Overall graft survival is shown. These results are cumulative of 5–10 independent experiments performed in
parallel. Log-rank (Mantel-Cox) test has been used (*p,0.01;**p,0.001; ***p,0.0001).
doi:10.1371/journal.pone.0028434.g001
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+
T cells isolated from mice treated with the combined protocol
produced more IL-10 than did those isolated from control mice
(Figure 4B), where the former also exert a powerful in vivo Ag-
specific suppressive function, as we previously showed [12].
Interestingly, although treatment with anti-CD45RB mAb alone
was not efficient in controlling graft rejection, it led to increased
frequency of splenic CD4
+IL-10
+IL4
2 T cells (Figure 4A).
Consequently, the CD4
+ T cells isolated from the spleen of the
same treated mice produced more IL-10 than did those isolated
from the spleen of control mice (Figure 4B).
Notably, no differences in the total number of CD4
+ T cells
were observed among untreated and treated (i.e., anti-CD45RB
mAb and combined) mice in the spleen, dLN and graft 30 days
(Figure S1) and 150 days (data not show) following islet transplant.
On the base of this, the frequencies of Foxp3
+ Treg and Tr1 cells
mirrored the differences in absolute number. Overall, these data
show that the combined treatment promotes both the expansion of
Foxp3
+ Treg cells in the graft and dLN, and the induction of
CD4
+IL-10
+IL4
2 T cells that accumulate in the spleen.
Long-term tolerance to allogeneic transplanted islets
endorsed by the combined protocol is associated with
splenic CD4
+IL-10
+IL-4
2 cells
To determine whether long-term tolerance (i.e., .150 days
following transplantation) observed in mice treated with the
combined protocol was still associated with the presence of Treg
cells, we analyzed the frequency of Foxp3
+ and CD4
+IL-10
+IL4
2
T cells in mice 50 days from donor-derived Ag re-challenge (i.e.,
150 days from transplantation). The Foxp3
+ Treg cells in the dLN
had expanded to levels similar to those in the dLN of mice
analyzed 30 days from transplantation, although said levels were
not statistically significant in comparison to levels identified in
untreated mice (Figure 5A). In the graft, the frequency of Foxp3
+
Treg cells did not differ statistically from that found in untreated
mice and was lower than that found 30 days following
transplantation (Figure 5A). The lack of splenic accumulation of
Foxp3
+ Treg cell was also confirmed at this later time point
(Figure 5A). The CD4
+IL-10
+IL4
2 T cells remained enriched in
the spleens of long-term tolerant mice (Figure 5B), and splenic
CD4
+ T cells produced high levels of IL-10 upon in vitro polyclonal
stimulation (Figure 5C). In a demonstration of their donor-
specificity, CD4
+ T cells isolated from the spleen of tolerant mice
produced IL-10 exclusively upon stimulation with original Ag (i.e.,
BALB-derived splenocytes) and not with third party Ag (i.e., C3H-
derived splenocytes) (Figure 5D).
We then tested whether the presence of Ag-specific CD4
+IL-
10
+IL4
2 T cells was associated with Ag-specific long-term
tolerance. The original graft was removed from long-term tolerant
mice, in which diabetes promptly resumed, and a second
transplant with islets isolated from the original donors or third-
party donors was performed. Only mice receiving third party islets
rejected the graft (Figure 5E), a finding that proved the
establishment of Ag-specific long-term tolerance in mice trans-
Figure 2. Anti-CD45RB mAb+rapamycin+IL-10 reduce CD45RB
high T cells and enrich CD4
+CD25
+Foxp3
+ T cells. Diabetic B6 mice were
transplanted with BALB islets and were either left untreated (n=3), or treated with anti-CD45RB mAb (n=4), or with the combined protocol (n=5).
(A) The frequencies of peripheral-blood CD4
+ (left) and CD8
+ (right) T cells within CD45
+CD3
+ cells are shown at different time points after the first
injection of the anti-CD45RB mAb. (B) The frequencies of peripheral-blood CD45RB
high effector T cells within CD45
+CD3
+CD4
+ cells (left) and within
CD45
+CD3
+CD8
+ cells (middle), and the frequencies of peripheral-blood CD25
+Foxp3
+ T cells within CD4
+ cells (right), are shown at different time
points after the first injection of anti-CD45RB mAb. One representative experiment out of 2 is shown. Means 6 SEM are shown.
doi:10.1371/journal.pone.0028434.g002
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protocol.
IL-10 is required for the maintenance of long-term
tolerance
The combined protocol promotes a state of long term-tolerance
associated with the accumulation IL-10-producing splenic CD4
+ T
cells. However, the role of IL-10 in this state of tolerance remains
unknown. In order to address this point, tolerant mice were
injected with anti-IL-10R mAb. Interestingly all the mice
promptly rejected the graft upon mAb injection (Figure 6A).
Although the number and the frequencies of Foxp3
+ T cells in
tolerant mice were not significantly higher as compared to those in
control mice, the combined treatment could have boost the
regulatory activity of Foxp3
+ T cells, for instance by increasing the
expression of CTLA-4 [20]. Therefore, one could still hypothesize
a role of these type of Treg cells in the maintenance of tolerance.
Interestingly, the depletion of Foxp3
+ T cells mediated by the
injection of anti-CD25 mAb (Figure S2) did not alter the state of
tolerance induced by the combined treatment (Figure 6B). These
data show the key role of IL-10 in the maintenance of tolerance
and suggest that Foxp3
+ T cells are not the IL-10-producers.
A clinically translatable protocol (G-CSF+rapamycin)
induces long-term tolerance
One important goal in the field of experimental (i.e., preclinical)
transplantation is to develop an immunomodulatory protocol that
is readily translatable to the clinic setting. Since recombinant IL-
10 is not available for clinical use, we chose to replace it with G-
CSF. G-CSF is a growth factor currently used for the clinical
mobilization of hematopoietic stem cells [27]. Importantly, both in
mice [21] and in humans [28], G-CSF has tolerogenic properties
that resemble those of IL-10. The combination of G-CSF+rapa-
mycin, in the absence of any depleting agents, led to long-term
graft survival in 80% of B6 mice transplanted with BALB islets (i.e.,
stringent model) (Figure 7A). Upon injection of donor-derived
splenocytes (i.e., donor-derived antigen boost) 100 days from
transplant, only 7 out of 25 mice with a long-term functioning
graft rejected the allogeneic islets. Overall, 58% of mice treated
with G-CSF+rapamycin achieved long-term tolerance (Figure 7A).
Finally, graft removal from all tolerant mice promptly induced a
return to hyperglycemia in each animal, and thus confirmed the
lack of any endogenous islet regeneration (Figure 7B).
Treated mice were analyzed, and increased percentages of
CD4
+IL-10
+IL4
2 T cells were found in the spleen 30 and 150
Figure 3. Localization of CD4
+Foxp3
+CD25
+ Treg cells in engrafted mice after the combined protocol. Diabetic B6 mice were
transplanted with BALB islets and were either left untreated (n=13), or treated with anti-CD45RB mAb (n=7), or with the combined protocol (n=7).
Thirty days after transplantation, treated mice were analyzed. Untreated control mice were analyzed once the graft was rejected. The frequencies of
CD25
+Foxp3
+ cells within CD4
+ cells in the spleen, in dLN, and in the graft are shown. Representative dot plots of the stainings are shown in the
upper panel, while the results collected from all mice analyzed are shown in the lower panel. Means 6 SEM are shown (*p,0.05;**p,0.005;
***p,0.0005).
doi:10.1371/journal.pone.0028434.g003
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+ Treg
cells were not found expanded in the spleen, dLN, or in the cells
infiltrating the graft; these findings were confirmed both at the end
of the treatment and in long-term tolerant mice (Figure 7D).
These data demonstrate that treatment with G-CSF+rapamycin
endorses long-term tolerance in a stringent mouse model of islet
transplantation, without any need for a deletion compound. Such
transplant tolerance is associated with the induction of splenic
CD4
+ with a Tr1-cell phenotype. However, further studies are
required to demonstrate the role of Tr1 cells for the maintenance
of tolerance upon G-CSF+rapamycin treatment.
Discussion
Firstly, we have proved that the combination of rapamycin, IL-
10 and anti-CD45RRB mAb is an efficient protocol to induce Ag-
specific tolerance as associated with two different types of Treg
cells localized in different tissues. Interestingly, the engraftment
Figure 4. Localization of CD4
+Foxp3
+CD25
+ Treg cells and ag-specific CD4
+IL-4
2IL-10
+ T cells in engrafted mice after the combined
protocol. Diabetic B6 mice were transplanted with BALB islets and were either left untreated (n=13), or treated with anti-CD45RB mAb (n=7), or
with the combined protocol (n=7). Thirty days after transplantation, treated mice were analyzed. Untreated control mice were analyzed once the
graft was rejected. (A) Representative dot plots of the intracellular stainings for the detection of IL-10 and IL-4 production by CD4
+ T cells from the
spleens and the dLN are shown in the left panel, while the results collected from all mice analyzed are shown in the right panel. (B) The amounts of
IL-10 (upper) and IL-4 (lower) released in vitro after polyclonal stimulation of CD4
+ T cells isolated from the spleen (left) or the dLN (right) are shown.
Cells isolated from spleen and dLN were cultured for 5 days in the presence of aCD3 (10 ug/ml) and aCD28 (1 ug/ml) mAbs. At the end of the culture
the cells were finally re-stimulated for 5 h in the presence of TPA/ionomycin to test the ability to produce IL-10 and IL-4 was tested by intracellular
staining. Means 6 SEM are shown (*p,0.05;**p,0.005).
doi:10.1371/journal.pone.0028434.g004
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+IL-4
2IL-10
+ T cells remain expanded in the spleen of tolerant mice and are associated with Ag-specific
tolerance. Diabetic B6 mice were transplanted with BALB islets and were either left untreated (n=8), or treated with the combined protocol (n=5).
Fifty days after boosting with donor-derived Ag (i.e., 150 days from transplantation), treated mice were analyzed. Untreated control mice were
analyzed once the graft was rejected. (A) The frequencies of CD25
+Foxp3
+ cells within CD4
+ cells in the spleen, in dLN, and in the graft are shown.
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+ Treg cells in the
target organ (i.e., graft) and of Ag-specific CD4
+IL-10
+IL-4
2 T
cells in the spleen. In contrast, long-term donor-specific trans-
plantation tolerance is characterized by a small collection of
Foxp3
+ Treg cells in dLN and by the maintenance of Ag-specific
CD4
+ IL-10
+ IL-4
2 T cells in the spleen. Accordingly the
tolerance is maintained by IL-10, while Foxp3
+ Treg cells are
dispensable. Secondly, we have shown that the combination of
rapamycin with G-CSF, two drugs already in clinical practices,
promotes long-term tolerance in the stringent mouse model of islet
transplantation. It is interesting to note that this tolerance was
again associated with the presence of CD4
+IL-10
+ IL-4
2 T cells in
the spleen of treated mice. However, the role of IL-10 and in turn
of Tr1 cells remains to be investigated.
Previous studies had already shown the transient deletion of
circulating lymphocytes following treatment with anti-CD45RB
mAb [18,19]. We have confirmed this phenomenon and
demonstrated that Foxp3
+ Treg cells are spared, while naı ¨ve/
effector CD4
+, CD8
+ T cells and B cells (data not shown) are the
main targets. The injection of anti-CD45RB mAb promotes
Foxp3
+ Treg-cell enrichment in the blood since the expression of
CD45RB by Foxp3
+ Treg cells is low [29]. The frequency of
Foxp3
+ Treg cells returns to normal levels upon the repopulation
of the blood with naive/effector CD4
+ and CD8
+ T cells. This
Figure 6. IL-10 and not CD4+ CD25+ Foxp3+ Treg cells is required to maintain long-term tolerance in transplanted mice upon the
combined treatment. Diabetic B6 mice were transplanted with BALB islets and were treated with the combined protocol. (A) The percentage for
graft survival (left) and the concentration of glycemia in the blood (right) of tolerant mice injected with the anti-IL-10R mAb (anti-IL-10R 1 mg/mouse)
or with PBS (vehicle) at 150 days transplantation are shown. (B) The percentage for graft survival (left) and the concentration of glycemia in the blood
(right) of tolerant mice injected with the low doe of anti-CD25 mAb (anti-CD25 mAb 1 mg/mouse), high dose (anti-CD25 mAb 3 mg/mouse) or with
PBS (vehicle) at 150 days after transplantation are shown.
doi:10.1371/journal.pone.0028434.g006
The dash bars report the frequencies of CD25
+Foxp3
+ cells within CD4
+ cells of transplanted mice treated with the combined protocol and sacrificed
30 days after transplantation. (B) The frequencies of IL-10
+IL-4
2 cells within splenic CD4
+ cells were detected by intracellular staining, and the results
collected from all mice analyzed are shown. (C) The amounts of IL-10 (upper) and IL-4 (lower) released in vitro after polyclonal stimulation of CD4
+ T
cells isolated from the spleen (left) or the dLN (right) are shown. (D) The amounts of IL-10 released from the splenic CD4
+ T cells in vitro after
stimulation with third party Ag (C3H) or donor-specific Ag (BALB) are shown. Means 6 SEM are shown (*p,0.05;**p,0.005; ***p,0.0005). (E)
Diabetic B6 mice were transplanted with islets from BALB mice and were treated with the combined protocol. One hundred days after
transplantation, the graft was removed and all the mice returned to being hyperglycemic. A second transplant was performed with islets isolated
either from the original donor (BALB, n=5) or from a third party donor (C3H, n=4). The percentages of graft survival following the second islet
transplant are shown.
doi:10.1371/journal.pone.0028434.g005
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PLoS ONE | www.plosone.org 8 December 2011 | Volume 6 | Issue 12 | e28434Figure 7. G-CSF+rapamycin induces long-term tolerance associated with splenic CD4
+IL-4
2IL-10
+ T cells. Diabetic B6 mice were
transplanted with BALB islets. (A) The transplanted mice were either left untreated (n=47) or treated with G-CSF alone (n=5) or with rapamycin+G-
CSF (n=30). The treatment was withdrawn 30 days after transplantation. One hundred days after transplantation, donor-derived splenocytes were
injected into tolerant mice to boost their immune system. Overall graft survival is shown. These results are cumulative of 2 independent experiments
performed in parallel. Log-rank (Mantel-Cox) test has been used (*p,0.01;**p,0.001;) (B) The graft was surgically removed from tolerant mice (n=5)
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mAb is combined with rapamycin+IL-10 treatment.
It is also known that the anti-CD45RB mAb fits the regulatory
properties of Foxp3
+ Treg cells by increasing the expression of
CTLA-4 and by promoting long-term graft survival [20]. We
confirm that increased CTLA-4 expression coincides with high
engraftment efficacy in anti-CD45RB mAb-treated mice. Howev-
er, none of these treated animals reached a state of long-term
tolerance. This result partially contrasts with previously published
data [30]. We suggest that these varying results could be explained
by: (I) differences in administration schedules; (II) differences in
gender ratios of the mice used as recipients and donors; and (III)
differences in approach used to verify the state of tolerance (e.g.,
boost with splenocytes versus a second transplantation). Impor-
tantly, we have clearly demonstrated that anti-CD45RB mAb
radically increases the efficacy of rapamycin+IL-10 treatment in
the stringent mouse model of islet transplantation.
Our data demonstrate that after the combined treatment,
Foxp3
+ Treg cells and CD4
+IL-10
+IL-4
2 T cells localized in
different organs. Data from mice and also from humans have
already reported that Foxp3
+ Treg cells occur in tolerant grafts
[31]. Other authors suggest that the presence of Foxp3
+ Treg cells
in dLN are key for their regulatory action [31]. In our model, we
observed Foxp3
+-Treg cells in the graft and in dLN 30 days from
transplantation, and their subsequent accumulation in the dLN of
long-term tolerant mice. This suggests that Foxp3
+ Treg cells may
migrate from the graft to dLN. In agreement with our hypothesis,
this Foxp3
+ Treg-cell migration (i.e., from the graft to dLN) has
been found to be a requisite for the blocking of islet allograft
rejection [32]. Interestingly, our data suggest that at later time
points, once immunological tolerance is established, the Foxp3
+
Treg cells slightly accumulate in the dLN and they are dispensable
for the maintenance of tolerance. Accordingly, studies performed
in mouse models of islet transplant have demonstrated that Foxp3
+
Treg cells are fundamental only during the early phase after
transplantation [33,34,35]. On the basis of this, one could
hypothesizes that Foxp3
+ Treg cells migrate to the graft at early
time points, exert their main role in situ, and become dispensable
lately once localized in the dLN.
Unlike the localization of Foxp3
+ Treg cells, Tr1 cells localize
mainly in the spleen, as we previously observed in various animal
models of tolerance [17,26] and as we reassert, with increased
evidence, in this study. It is especially interesting to note that
splenic DCs alone have the capacity, in the presence of TGF-b,t o
induce Tr1 cells [36]. However, the issue of whether the spleen is
the key organ for Tr1-cell regulatory activity is still inadequately
addressed.
All in all, the combined treatment promoted a state of tolerance
that was associated with two different types of Treg cells, which in
turn localized in differing tissues. This model represents a unique
opportunity to study some still ill-defined aspects of the biology of
Foxp3
+ Treg and Tr1 cells: whether, where and how these two
different types of Treg cells work together to induce and promote
transplantation tolerance.
Exogenous treatment with recombinant IL-10 has not clearly
demonstrated beneficial effects in a number of clinical trials [37],
and at present is not clinically available. On this basis, we
developed a new combined protocol that uses previously approved
compounds. G-CSF is used for the mobilization of stem cells, and
it shows tolerogenic capacities that are interestingly similar to
those of the IL-10 treatment [27]. We accordingly substituted IL-
10 with G-CSF; without using any depleting agents, and against all
expectation, the combination of rapamycin+G-CSF promoted
tolerance in the stringent mouse model of islet transplantation.
Although it is known that G-CSF promotes the in vivo expansion
of CD4
+CD25
+ T cells [22,23], we could not find any enrichment
of these cells in any target organs of treated mice. Differences in G-
CSF administration schedules and/or the combination with
rapamycin could explain why our data vary from previous
findings.
It is also known that G-CSF promotes the release of IL-10 from
human and mouse CD4
+ T cells [21,28]. In turn, we find a strong
in vivo expansion of splenic CD4
+ IL-10
+ IL-4
2 T cells, both
under the umbrella of the treatment and in tolerant mice.
Although the cytokine profile of CD4
+ IL-10
+ IL-4
2 T cells found
in the spleen of treated mice reflects that of Tr1 cells, future efforts
must verify their regulatory capacity. We are currently developing
new tools that will selectively isolate or delete Tr1 cells as a way to
understand their specific role in the induction of tolerance. Finally,
it is interesting to note that two different treatments induce CD4
+
IL-10
+ IL-4
2 T cells, which in both cases localize in the spleen and
occur in tolerant mice.
Materials and Methods
Mice and islet transplant
BALB/c (BALB) and C57BL/6 (B6) female mice were
purchased from Charles River (Calco, Italy). All mice were
maintained under specific pathogen-free conditions. Diabetes was
induced by intravenous (i.v.) injection of 170 mg/kg streptozotocin
(Sigma-Aldrich, St. Louis, MO). Glucose levels in tail venous
blood were quantified with the Glucometer Elite system (Bayer,
Wuppertal, Germany), and measurements invariably took place in
the morning. Pancreatic islet transplant was performed as
previously described [17]. Graft rejection was diagnosed on the
basis of two sequential glucose measurements .300 mg/dl.
The transplanted mice that did not reject the graft 100 days
after transplantation were boosted in vivo with donor-origin
splenocytes. A total of 30610
6 splenocytes isolated from the
original islet donors were injected intraperitoneally (i.p.), and blood
glucose levels were monitored daily thereafter. Mice still
normoglycemic 30–50 days from boosting were considered long-
term tolerant. The study was approved by the San Raffaele
Hospital Institutional Animal Care and Use Committee (permit
no IACUC 350).
Treatment of transplanted mice
Transplanted mice were treated with anti-CD45RB mAb
(MB23G2 clone from ATCC) alone or with the addition of
rapamycin (Rapamune; Wyeth Europe, Taplow, U.K.)+r-hu-IL-
10 (BD Pharmingen, San Diego, CA). Anti-CD45RB mAb was
injected i.v. at days 0, 1, and 5 following transplantation at 100 mg
to verify graft functionality. Glycemia levels in the blood of each mouse tested are shown. (C) The frequencies of IL-10
+IL-4
2 T cells within splenic
CD4
+ T cells 30 (left) and 150 (right) days after transplantation in control untreated (n=5) and rapamycin+G-CSF–treated (n=5) mice are shown. Cells
isolated from spleen and dLN were cultured for 5 days in the presence of aCD3 (10 ug/ml) and aCD28 (1 ug/ml) mAbs. At the end of the culture the
cells were finally restimulated for 5 h in the presence of TPA/ionomycin to test the ability to produce IL-10 and IL-4 was tested by intracellular
staining. (D) The frequencies of CD25
+Foxp3
+ T cells within CD4
+ cells in the spleen, in dLN and in graft 30 (upper) and 150 days (lower) after
transplantation in control untreated (n=5) and rapamycin+G-CSF–treated (n=5) mice are shown. Means 6 SEM are shown (*p,0.05;**p,0.005).
doi:10.1371/journal.pone.0028434.g007
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gavage for 30 consecutive days once a day at 1 mg/kg.
Recombinant hu-IL-10 was diluted in PBS and administered i.p.
twice a day for 30 consecutive days at 0.05 mg/kg. G-CSF
(Myelostim, rHuG-CSF, Italfarmaco) was diluted in PBS and
injected s.c. for 30 consecutive days at 200 mg/kg. Neither
treatments with the vehicles (water, PBS), nor with the isotype
control for anti-CD45RB mAb (Rat IgG2a), following the same
administration and schedule of the original treatments, show any
delay in the survival of the graft respect to untreated mice (data not
shown).
Some tolerant mice (combined treatment) were injected either
with the anti-IL-10 receptor (anti-IL-10R) (1B1.2 clone from
ATCC, Manassas, VA) or with the anti-CD25Ra (PC61 clone
from ATCC) monoclonal antibody (mAb). The anti-IL-10R mAb
diluted in PBS (vehicle) was administered i.p. for three consecutive
days to reach a dose of 1 mg/mouse. The PC61 mouse (500 mg/
mouse/dose) was diluted in PBS (vehicle) and administered i.p. for
two consecutive days every week for either 1 or 3 weeks to reach
the dose of 1 mg/mouse and 3 mg/mouse respectively. The doses
of anti-IL-10R and PC61 mAbs were chosen in accordance with
the literature [17,33,34].
Cell isolation
Spleen, dLN and graft were isolated from transplanted mice and
mashed to yield single cell suspensions. Splenic CD4
+ T cells were
magnetically isolated in accordance with the protocol of the
‘‘CD4
+ T cell isolation kit’’ (Miltenyi Biotec, Bergisch Gladbach,
German; purity 90–95%).
Cell staining and enzyme-linked immunosorbent assay
Surface cell staining was performed with anti-CD45 PercP, anti-
CD3 APC, anti-CD4 Pacific Blue, anti-CD25 APC or PeCy7, and
anti-CD8 PE mAbs (all from BD Pharmingen). The CD45RB
expression was tested with the anti-CD45RB PE mAb (clone 16A
from BD Pharmingen), which had previously been demonstrated
to bind to an epitope different than that bound by MB23G2 mAb
[20]. Foxp3 expression was tested with the Foxp3 staining kit
(eBioscience, San Diego, California; clone FjK-16s). Intracellular
staining and ELISA were performed as previously described [12].
Cells were acquired on a FACSCanto (BD Bioscience) and
analyzed with FCS express V3 (De Novo Software, Los Angeles,
CA).
Statistical analysis
Differences between groups were assessed with the Student t
test. P values were two-tailed with a confidence of 95%. Islet
allograft survivals were determined with Kaplan-Meier survival
curves, and were compared by means of the log-rank test.
Statistical analysis was performed with the Prism V4.03 software
(Graph-Pad, San Diego, California USA).
Supporting Information
Figure S1 Diabetic B6 mice were transplanted with
BALB islets and were either left untreated (Untreated),
or treated with anti-CD45RB mAb (aCD45RB), com-
bined protocol (Combine), G-CSF (C-CSF) and rapamy-
cin plus G-CSF (rapamycin+G-CSF). Thirty days after
transplantation, treated mice were analyzed. Untreated control
mice were analyzed once the graft was rejected. The total number
of CD4+ T cells within CD45+ cells in the spleen, in dLN, and in
the graft is shown. Results are cumulative from three independent
experiments. The study was approved by the San Raffaele
Hospital Institutional Animal Care and Use Committee (permit
no IACUC 350).
(TIF)
Figure S2 B6 mice were injected i.v. with 1 mg (2
injections) or with 3 mg (6 injections) of anti-CD25
mAb (clone PC61) and 7 days after the last injection the
% of CD25+ Foxp3+ within CD4+ T cells in the blood,
spleen and mLN were analyzed. The clone 7D4 for mAb
anti-CD25 has been used for the FACS staining. The study was
approved by the San Raffaele Hospital Institutional Animal Care
and Use Committee (permit no IACUC 350).
(TIF)
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